Program
efzimfotase alfa
Its studies are mostly in Hypophosphatasia, led by AstraZeneca.
Furthest: phase 3, since Oct 6, 20233 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 32 open or running | phase 3since Oct 6, 2023 | Jul 23, 2021 | none ahead |
- Named in AstraZeneca’s own pipeline as
efzimfotase alfa
, phase 4, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2021First study: phase 1 study in HypophosphatasiaFirst studyNCT04980248 · 15 enrolled · United States
- Oct 6, 20232 phase 3 studies in HypophosphatasiaNCT06079359, NCT06079281
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06079359Hypophosphatasia · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jan 6, 2026 | 30 |
| NCT06079281Hypophosphatasia · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 9, 2025 | 124 |
| NCT04980248Hypophosphatasia · United States | 1 | Completed | Aug 24, 2022 | 15 |
How it is read
Names in the registry
- “ALXN1850”, 3 entries
Conditions, from the studies’ own filings
- Hypophosphatasia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.